医学
中止
荟萃分析
随机对照试验
内科学
黑色素瘤
不利影响
肿瘤科
封锁
癌症研究
受体
作者
Maurício Fernando Silva Almeida Ribeiro,Camila Bragança Xavier,Allan Andresson Lima Pereira,Mariana Scaranti,Luiza Dib Batista Bugiato Faria,Tatiana Correa,Marina Sahade,David Queiroz Borges Muniz,Olavo Feher,Gustavo dos Santos Fernandes,Artur Katz,Rodrigo Ramella Munhoz
出处
期刊:Brazilian Journal of Oncology
[GN1 Genesis Network]
日期:2022-01-01
卷期号:18
被引量:1
标识
DOI:10.5935/2526-8732.20220298
摘要
OBJECTIVES: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We sought to evaluate efficacy and safety of first-line combination ICI and BRAF/MEK inhibitors (triplets) versus BRAF/MEKi (doublets). METHODS: We performed a systematic review and meta-analysis of RCT comparing triplet versus doublet published in MEDLINE and EMBASE from 2016-September/2020. We obtained pooled effect estimates through random-effects model assuming p<0.05 as statistically significant. RESULTS: Among 1,784 studies, 3 RCT were selected. Triplets demonstrated progression-free survival (PFS) (HR 0.79 - CI 0.68-0.91, p=0.001) and overall survival (OS) improvement (HR 0.81 - CI 0.67-0.98, p=0.03), with increased rates of grades 3/4 adverse events (AEs), any grade pyrexia, arthralgia, and aminotransferases elevation. AE-discontinuation rates of all drugs remained similar. CONCLUSIONS: Triplets improved PFS and OS with manageable toxicities. These are preliminary results and mature data are expected.
科研通智能强力驱动
Strongly Powered by AbleSci AI